Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.62 | N/A | +588.89% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.62 | N/A | +588.89% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management highlighted the unexpected EPS performance but did not provide additional insights or future guidance. The tone remained neutral regarding future expectations.
Management did not provide specific guidance for future quarters.
The company reported a significant surprise in EPS, indicating better-than-expected performance.
Ligand Pharmaceuticals reported a strong EPS figure that significantly exceeded expectations, showcasing its ability to generate profits. However, the stock fell by nearly 3% in reaction to the earnings report, which may suggest investor concerns about the lack of revenue details and future guidance. Without clear direction from management, investors may remain cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 31, 2016